within Pharmacolibrary.Drugs.ATC.C;

model C10AX16
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0024,
    adminDuration  = 600,
    adminMass      = 284 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.5,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.525,
    k12             = 14.1,
    k21             = 14.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10AX16</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Inclisiran is a small interfering RNA (siRNA) drug that targets and degrades PCSK9 mRNA in the liver, leading to lower levels of LDL cholesterol. It is used in the treatment of hypercholesterolemia and is approved for use in adults with elevated LDL-C who are at high risk for cardiovascular events.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult subjects with hypercholesterolemia or mixed dyslipidemia after a single subcutaneous dose.</p><h4>References</h4><ol><li><p>Ray, KK, et al., &amp; Kastelein, JJP (2020). Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. <i>The New England journal of medicine</i> 382(16) 1507–1519. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1912387&quot;>10.1056/NEJMoa1912387</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32187462/&quot;>https://pubmed.ncbi.nlm.nih.gov/32187462</a></p></li><li><p>Yamashita, S, et al., &amp; Kajinami, K (2024). Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15. <i>Journal of atherosclerosis and thrombosis</i> 31(6) 876–903. DOI:<a href=&quot;https://doi.org/10.5551/jat.64454&quot;>10.5551/jat.64454</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38220186/&quot;>https://pubmed.ncbi.nlm.nih.gov/38220186</a></p></li><li><p>Kallend, D, et al., &amp; Wijngaard, P (2022). Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. <i>Journal of clinical lipidology</i> 16(2) 208–219. DOI:<a href=&quot;https://doi.org/10.1016/j.jacl.2022.01.001&quot;>10.1016/j.jacl.2022.01.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35168913/&quot;>https://pubmed.ncbi.nlm.nih.gov/35168913</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10AX16;
